Patents Assigned to Takeda
  • Oral administration form for pyridin-2-ylmethylsulfinyl-1H benzimidazoles
    Patent number: 8465767
    Abstract: The invention relates to an oral administration form for pyridin-2-ylmethylsulfinyl-1H-benzimidazoles and their salts, which comprises the active compound together with tablet disintegrants and is provided with a film coating customary per se for sustained-release compositions.
    Type: Grant
    Filed: May 21, 2008
    Date of Patent: June 18, 2013
    Assignee: Takeda GmbH
    Inventors: Rango Dietrich, Hartmut Ney
  • Heterocyclic compound and use thereof
    Patent number: 8466282
    Abstract: Compounds represented by the formulas (I) (II) wherein each symbol is as defined in the specification, and a prodrug thereof have a superior renin inhibitory activity, and are useful as agents for the prophylaxis or treatment of hypertension, various organ damages attributable to hypertension and the like.
    Type: Grant
    Filed: June 17, 2009
    Date of Patent: June 18, 2013
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Takanobu Kuroita, Yasuhiro Imaeda, Kouichi Iwanaga, Naohiro Taya, Hidekazu Tokuhara, Yoshiyuki Fukase
  • Multiple PPI dosage form
    Patent number: 8461187
    Abstract: Herein provided are dosage forms (variously referred to as “formulations”) comprising a PPI that is released from the dosage form as a first and a second dose. Each dose of PPI is present in an amount sufficient to raise the plasma levels of the PPI to at least 100 ng/ml.
    Type: Grant
    Filed: June 1, 2005
    Date of Patent: June 11, 2013
    Assignee: Takeda Pharmaceuticals U.S.A., Inc.
    Inventors: Rajneesh Taneja, Majid Vakilynejad
  • Heterocyclic derivative and use thereof
    Patent number: 8461348
    Abstract: The present invention aims to provide a compound having superior pharmacological action, physicochemical properties and the like and useful as an sGC activation drug, or an agent for the prophylaxis and/or treatment of diseases such as hypertension, ischemic cardiac disease, cardiac failure, kidney disease, arteriosclerotic disease, atrial fibrillation, pulmonary hypertension, diabetes, diabetic complications, metabolic syndrome, peripheral arterial obstruction, erectile dysfunction and the like. An sGC activation drug containing a compound represented by the formula (II): wherein each symbol is as defined in the specification, or a salt thereof, as an active ingredient.
    Type: Grant
    Filed: April 3, 2009
    Date of Patent: June 11, 2013
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Nobuyuki Matsunaga, Yoshihisa Nakada, Yusuke Ohba, Hideyuki Nakagawa
  • Substituted N-(pyrazolo[1,5-a]pyrimidin-5-yl)amides as inhibitors of apoptosis signal-regulating kinase 1
    Patent number: 8461163
    Abstract: The present invention relates to apoptosis signal-regulating kinase 1 (“ASK1”) . inhibiting compounds of the formula wherein the variables are as defined herein. The invention also relates to pharmaceutical compositions, kits and articles of manufacture comprising such compounds, to methods and intermediates useful for making the compounds, and to methods of using the compounds.
    Type: Grant
    Filed: March 30, 2009
    Date of Patent: June 11, 2013
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Edcon Chang, Tracy Duong, Takehiro Hirano, Matthew H. McNiell, Yoshito Terao, Angie Vassar
  • HUMIDIFIED PARTICLES COMPRISING A THERAPEUTICALLY ACTIVE SUBSTANCE
    Publication number: 20130142782
    Abstract: The invention relates to aerosolized and humidified particles comprising a therapeutically active substance which can be obtained by suspending dry inhalable particles in a carrier gas, adding water vapor and causing condensation of water on the particles. The invention further relates to methods to generate these particles, and apparatus useful to carry out such methods.
    Type: Application
    Filed: August 22, 2011
    Publication date: June 6, 2013
    Applicant: TAKEDA GMBH
    Inventors: Daniela Rahmel, Friedemann Taut, Christian De Muynck, Markus Rast, Peter Iwatschenko, Gerhard Pohlmann, Wolfgang Koch, Horst Windt
  • METHODS FOR PRESERVING AND/OR INCREASING RENAL FUNCTION USING XANTHINE OXIDOREDUCTASE INHIBITORS
    Publication number: 20130143886
    Abstract: The present invention relates to methods of preserving or increasing renal function in a subject in need thereof by administering a therapeutically effective amount of at least one xanthine oxidoreductase inhibiting compound or salt thereof. The present invention also relates to methods of increasing renal function in a subject in need thereof by administering a therapeutically effective amount of at least one xanthine oxidoreductase inhibiting compound or salt thereof.
    Type: Application
    Filed: January 30, 2013
    Publication date: June 6, 2013
    Applicant: Takeda Pharmaceuticals U.S.A., Inc.
    Inventor: Takeda Pharmaceuticals U.S.A., Inc.
  • Hydroxy-6-heteroarylphenanthridines and their use as PDE4 inhibitors
    Patent number: 8455653
    Abstract: Compounds of the formula Ia***** in which the substituents have the definitions provided in the specification, are novel, effective PDE4 inhibitors, useful in the treatment of psoriasis.
    Type: Grant
    Filed: October 26, 2012
    Date of Patent: June 4, 2013
    Assignee: Takeda GmbH
    Inventor: Ulrich Kautz
  • Compositions for treatment of common cold
    Patent number: 8450339
    Abstract: New stable compositions comprising the combination of a topically active vasoconstrictor and a topically active anticholinergic drug are disclosed. Preferably, the composition comprises ipratropium or a salt thereof in combination with xylometazoline hydrochloride and a salt thereof. Upon topically administering such compositions to a nasal mucosa in individuals suffering from the common cold the symptoms of rhinorrhea are significantly reduced.
    Type: Grant
    Filed: December 11, 2009
    Date of Patent: May 28, 2013
    Assignee: Takeda Pharma A/S
    Inventors: Hanne Anette Moesgaard, Karin Lowenstein Christensen
  • Substituted derivatives of pyrido[3,2-e][1,4]thiazino[4,3-a]pyrazine and pyrido[3,2-e][1,4]oxazino[4,3-a]pyrazine
    Patent number: 8450323
    Abstract: Disclosed are compounds of the following formula: in which R1, R2, R6, R7, R12, X, and q are defined in the specification. Also disclosed are pharmaceutical compositions, kits, and articles of manufacture, which contain the compounds, methods and intermediates useful for making the compounds, and methods of using the compounds to treat diseases, disorders, and conditions related to PARP activity.
    Type: Grant
    Filed: January 18, 2012
    Date of Patent: May 28, 2013
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Anthony R. Gangloff, Andrew John Jennings, Benjamin Jones, Andre A. Kiryanov
  • Method for screening of cell-protecting agent
    Patent number: 8450070
    Abstract: The invention provides a screening method and screening kit for a cell protecting agent. Specifically, the invention provides a method for screening a cell protecting agent showing an Hsp90-binding activity and a heat shock protein expression-inducing activity but having no Hsp90 client protein degradation-promoting activity. The method comprises the following steps (1) to (3): (1) measuring the binding property of a test compound to Hsp90; (2) measuring the activity of a test compound to induce the expression of a heat shock protein, or measuring the activity of a test compound to disrupt an Hsp90/HSF-1 complex, by using a cell capable of expressing the heat shock protein; and (3) measuring the activity of a test compound to induce the degradation of an Hsp90 client protein by using a cell capable of expressing the Hsp90 client protein.
    Type: Grant
    Filed: December 26, 2008
    Date of Patent: May 28, 2013
    Assignee: Takeda Pharmaceutical Company Limited
    Inventor: Haruhide Kimura
  • Drug composition having active ingredient adhered at high concentration to spherical core
    Patent number: 8449911
    Abstract: Granule, fine particle or tablet of excellent leaching property, comprising a drug active ingredient in high content realized by forming a layer containing drug active ingredient on core particles through a combination of a method of dispersing and adhering an active ingredient while spraying or adding a binder with a method of spraying or adding a solution or suspension wherein an active ingredient and a binder are contained so as to effect adhesion. Further, there are provided a drug composition containing such a granule, fine particle or tablet and a process for producing the same.
    Type: Grant
    Filed: March 10, 2004
    Date of Patent: May 28, 2013
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Shuji Yoneyama, Hiroto Bando
  • FUSED HETEROCYCLIC COMPOUND AND APPLICATION THEREOF
    Publication number: 20130131050
    Abstract: The present invention provides a compound useful for the prophylaxis or treatment of eicosanoid-associated diseases such as atherosclerosis, atherothrombosis, diabetes, obesity, asthma, fever, pain, cancer, rheumatism, osteoarthritis, atopic dermatitis and the like, and having superior pharmacological action, physicochemical properties and the like. The present invention relates to a compound represented by the following formula: wherein each symbol is as defined in the specification, or a salt thereof.
    Type: Application
    Filed: July 22, 2011
    Publication date: May 23, 2013
    Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Nobuyuki Matsunaga, Hideo Suzuki, Kouhei Asano, Hidekazu Tokuhara, Takeshi Yamamoto, Rei Okamoto
  • Substituted 7-carboxamido-pyrrolo[3,2-d]pyrimidines
    Patent number: 8445501
    Abstract: The compounds of Formula (I), in which R1, R21, R22, R23, R24, Y and R3 have the meanings as given in the description, the salts thereof, the N-oxides of the compounds and the salts thereof and the stereoisomers of the compounds, the salts, the N-oxides of the compounds and the N-oxides of the salts thereof are effective inhibitors of the type 5 phosphodiesterase.
    Type: Grant
    Filed: February 25, 2009
    Date of Patent: May 21, 2013
    Assignee: Takeda GmbH
    Inventors: Josef Stadlwieser, Beate Schmidt, Heiko Bernsmann, Alexander Sudau, Torsten Dunkern, Degenhard Marx, Jörg Diefenbach
  • Pharmaceutical composition for meniere's disease
    Patent number: 8445461
    Abstract: The present invention provides pharmaceutical composition for treating Meniere's disease, comprising saccharides or sugar alcohols as an active ingredient and polysaccharides, wherein the ratio by weight of the saccharides or sugar alcohols to the polysaccharides is about 100:2 to 100:50. The pharmaceutical composition of the present invention may eliminate the cathartic effect caused by saccharides or sugar alcohols to ensure the endolymphatic hydrops decompression effect. Therefore the effect of the therapeutic composition of the present invention is improved. The pharmaceutical composition may provide in gel, powder, granule form or the like.
    Type: Grant
    Filed: January 10, 2007
    Date of Patent: May 21, 2013
    Assignee: Setsuko Takeda
    Inventor: Setsuko Takeda
  • Fused heterocyclic derivatives and use thereof
    Patent number: 8445509
    Abstract: The present invention provides a fused heterocyclic derivative having a strong kinase inhibitory activity and use thereof. The present invention relates to a compound represented by the formula wherein each symbol is as defined in the present specification, or a salt thereof.
    Type: Grant
    Filed: May 7, 2009
    Date of Patent: May 21, 2013
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Naoki Miyamoto, Shigemitsu Matsumoto, Shinichi Imamura
  • Methods for concomitant administration of colchicine and a second active agent
    Patent number: 8445541
    Abstract: Methods for concomitant administration of colchicine together with one or more second active agents, e.g., verapamil, are disclosed. Such methods reduce the dangers commonly associated with such concomitant administration and provide additional benefits. Methods of notifying health care practitioners and patients regarding appropriate dosing for concomitant administration of colchicine together with second active agents are also provided.
    Type: Grant
    Filed: April 24, 2012
    Date of Patent: May 21, 2013
    Assignee: Takeda Pharmaceuticals U.S.A., Inc.
    Inventor: Matthew W. Davis
  • Stabilized pharmaceutical product
    Patent number: 8440210
    Abstract: Use of an adsorbent and a sealed package (e.g. an overwrap) to protect a pharmaceutical product in a solid state in the presence of a reducing sugar.
    Type: Grant
    Filed: April 2, 2012
    Date of Patent: May 14, 2013
    Assignee: Takeda GmbH
    Inventors: Zoe Heaton, David Goodwin, Iain Breakwell
  • Methods for concomitant administration of colchicine and a second active agent
    Patent number: 8440721
    Abstract: Methods for concomitant administration of colchicine together with one or more second active agents, e.g., ketoconazole and ritonavir, are disclosed. Such methods reduce the dangers commonly associated with such concomitant administration and provide additional benefits. Methods of notifying health care practitioners and patients regarding appropriate dosing for concomitant administration of colchicine together with second active agents are also provided.
    Type: Grant
    Filed: July 18, 2011
    Date of Patent: May 14, 2013
    Assignee: Takeda Pharmaceuticals U.S.A., Inc.
    Inventor: Matthew W. Davis
  • Methods for concomitant administration of colchicine and a second active agent
    Patent number: 8440722
    Abstract: Methods for concomitant administration of colchicine together with one or more second active agents, e.g., verapamil, are disclosed. Such methods reduce the dangers commonly associated with such concomitant administration and provide additional benefits. Methods of notifying health care practitioners and patients regarding appropriate dosing for concomitant administration of colchicine together with second active agents are also provided.
    Type: Grant
    Filed: April 24, 2012
    Date of Patent: May 14, 2013
    Assignee: Takeda Pharamceuticals U.S.A., Inc.
    Inventor: Matthew W. Davis